JP2022507025A5 - - Google Patents
Info
- Publication number
- JP2022507025A5 JP2022507025A5 JP2021524166A JP2021524166A JP2022507025A5 JP 2022507025 A5 JP2022507025 A5 JP 2022507025A5 JP 2021524166 A JP2021524166 A JP 2021524166A JP 2021524166 A JP2021524166 A JP 2021524166A JP 2022507025 A5 JP2022507025 A5 JP 2022507025A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition according
- represents hydrogen
- phenyl
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025006295A JP2025063207A (ja) | 2018-11-08 | 2025-01-16 | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841042108 | 2018-11-08 | ||
| IN201841042108 | 2018-11-08 | ||
| PCT/IB2019/059602 WO2020095256A1 (en) | 2018-11-08 | 2019-11-08 | Combination of small molecule cd-47 inhibitors with other anti-cancer agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006295A Division JP2025063207A (ja) | 2018-11-08 | 2025-01-16 | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507025A JP2022507025A (ja) | 2022-01-18 |
| JP2022507025A5 true JP2022507025A5 (enExample) | 2022-11-11 |
| JP7623279B2 JP7623279B2 (ja) | 2025-01-28 |
Family
ID=69159806
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524166A Active JP7623279B2 (ja) | 2018-11-08 | 2019-11-08 | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
| JP2025006295A Pending JP2025063207A (ja) | 2018-11-08 | 2025-01-16 | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006295A Pending JP2025063207A (ja) | 2018-11-08 | 2025-01-16 | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11311517B2 (enExample) |
| EP (1) | EP3876931A1 (enExample) |
| JP (2) | JP7623279B2 (enExample) |
| KR (1) | KR20210088584A (enExample) |
| CN (2) | CN120305258A (enExample) |
| AU (1) | AU2019375193A1 (enExample) |
| BR (1) | BR112021008781A2 (enExample) |
| CA (1) | CA3118843A1 (enExample) |
| EA (1) | EA202190776A1 (enExample) |
| IL (1) | IL282972B2 (enExample) |
| MX (2) | MX2021005240A (enExample) |
| PH (1) | PH12021550832A1 (enExample) |
| SG (1) | SG11202104192TA (enExample) |
| WO (1) | WO2020095256A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3087841A1 (en) * | 2018-01-12 | 2019-07-18 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways |
| JP2024508395A (ja) * | 2021-02-10 | 2024-02-27 | グレート ノベル セラピューティクス バイオテック アンド メディカルズ コーポレイション | がんに対する免疫応答を刺激する又は免疫抑制を克服するための医薬組み合わせ及び方法 |
| CN113018415B (zh) * | 2021-03-17 | 2022-07-01 | 遵义医科大学 | 一种药物组合及其应用 |
| CN113750215B (zh) * | 2021-09-24 | 2023-06-23 | 暨南大学 | 用于治疗肿瘤的联合药物 |
| AU2024363740A1 (en) | 2023-10-19 | 2026-04-02 | Aurigene Oncology Limited | Pharmaceutically acceptable salt of a cd47-sirp alpha pathway inhibitor |
| WO2025229631A2 (en) * | 2024-05-03 | 2025-11-06 | Aurigene Oncology Limited | A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER |
| WO2025229629A1 (en) | 2024-05-03 | 2025-11-06 | Aurigene Oncology Limited | Combination therapy using a cd47-sirp-alpha blocking agent and azacitidine |
| CN118453879B (zh) * | 2024-05-23 | 2025-10-03 | 大连医科大学附属第二医院 | 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2104501B1 (en) * | 2006-12-13 | 2014-03-12 | Merck Sharp & Dohme Corp. | Methods of cancer treatment with igf1r inhibitors |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| HUE038169T2 (hu) | 2013-09-06 | 2018-09-28 | Aurigene Discovery Tech Ltd | 1,2,4-Oxadiazol származékok mint immunomodulátorok |
| BR112017019304A2 (pt) | 2015-03-10 | 2018-05-08 | Aurigene Discovery Technologies Limited | compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores |
| KR102894264B1 (ko) * | 2015-03-10 | 2025-12-02 | 오리진 온콜로지 리미티드 | 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물 |
| EP3283175B1 (en) | 2015-04-14 | 2026-05-06 | The Procter & Gamble Company | Solid conditioning composition |
| CN104804093A (zh) | 2015-05-27 | 2015-07-29 | 江苏春申堂药业有限公司 | 一种针对cd47的单域抗体 |
| WO2017053423A1 (en) | 2015-09-21 | 2017-03-30 | Erasmus University Medical Center | Anti-cd47 antibodies and methods of use |
| EP3454879B1 (en) | 2016-05-10 | 2021-12-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New compounds and pharmaceutical use thereof in the treatment of cancer |
| EP3243522A1 (en) | 2016-05-10 | 2017-11-15 | Université Pierre et Marie Curie (Paris 6) | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death |
| WO2018047139A1 (en) * | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Compounds as modulators of tigit signalling pathway |
| AU2017345500B2 (en) * | 2016-10-20 | 2022-03-10 | Aurigene Oncology Limited | Dual inhibitors of vista and PD-1 pathways |
| CA3087841A1 (en) * | 2018-01-12 | 2019-07-18 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways |
| CN118236374A (zh) * | 2018-03-14 | 2024-06-25 | 奥瑞基尼肿瘤有限公司 | 使用1,2,4-噁二唑化合物调节tigit和pd-1信号传导途径的方法 |
-
2019
- 2019-11-08 EP EP19835717.0A patent/EP3876931A1/en not_active Withdrawn
- 2019-11-08 SG SG11202104192TA patent/SG11202104192TA/en unknown
- 2019-11-08 BR BR112021008781-8A patent/BR112021008781A2/pt unknown
- 2019-11-08 AU AU2019375193A patent/AU2019375193A1/en not_active Abandoned
- 2019-11-08 CA CA3118843A patent/CA3118843A1/en active Pending
- 2019-11-08 US US16/678,594 patent/US11311517B2/en active Active
- 2019-11-08 MX MX2021005240A patent/MX2021005240A/es unknown
- 2019-11-08 CN CN202510514794.1A patent/CN120305258A/zh active Pending
- 2019-11-08 JP JP2021524166A patent/JP7623279B2/ja active Active
- 2019-11-08 EA EA202190776A patent/EA202190776A1/ru unknown
- 2019-11-08 WO PCT/IB2019/059602 patent/WO2020095256A1/en not_active Ceased
- 2019-11-08 IL IL282972A patent/IL282972B2/en unknown
- 2019-11-08 CN CN201980071532.5A patent/CN112930181B/zh active Active
- 2019-11-08 KR KR1020217014395A patent/KR20210088584A/ko not_active Ceased
-
2021
- 2021-04-13 PH PH12021550832A patent/PH12021550832A1/en unknown
- 2021-05-04 MX MX2024006094A patent/MX2024006094A/es unknown
-
2022
- 2022-04-25 US US17/728,325 patent/US12268670B2/en active Active
-
2025
- 2025-01-16 JP JP2025006295A patent/JP2025063207A/ja active Pending
- 2025-02-04 US US19/045,376 patent/US20250177358A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022507025A5 (enExample) | ||
| JP2024531477A5 (enExample) | ||
| ES2808988T3 (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| JP6514647B2 (ja) | 薬物組み合わせ | |
| RU2018130330A (ru) | Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией | |
| JP2022141916A5 (enExample) | ||
| JP7623279B2 (ja) | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ | |
| UA126421C2 (uk) | Інгібітори pd-1/pd-l1 | |
| TW201740943A (zh) | Hdac抑制劑與pd-1抑制劑之組合治療 | |
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| HRP20210848T1 (hr) | Sastavi i postupci za sprječavanje aktivnosti arginaze | |
| JP2021113206A (ja) | ２−（４−クロロフェニル）−ｎ−（（２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン−５−イル）メチル）−２，２−ジフルオロアセトアミドの製剤 | |
| JP2022537358A5 (enExample) | ||
| CN111836621A (zh) | 使用1,2,4-噁二唑化合物调节tigit和pd-1信号传导途径的方法 | |
| JP2024522304A5 (enExample) | ||
| JP2021528496A5 (enExample) | ||
| CN111973747A (zh) | 用于联合治疗卵巢癌的喹啉衍生物 | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| TW202340142A (zh) | Ｇｃｌ抑制劑 | |
| RU2025105118A (ru) | Комбинированная терапия ингибиторами cdk7 с другими противораковыми агентами | |
| RU2025135585A (ru) | Кристаллическая форма ингибитора enpp1 | |
| EA045738B1 (ru) | Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами |